Fri Sep 20 12:16:16 UTC 2024: ## ICON Public (ICLR) Stock Sees Price Target Cut, but Remains a Buy

**New York, NY – September 20, 2024** – Shares of ICON Public (NASDAQ:ICLR) saw their price target lowered by analysts at Robert W. Baird, despite the firm maintaining an “outperform” rating on the medical research company. The new target of $340.00 represents a potential upside of 12.99% from the company’s previous close.

This adjustment comes amidst a mixed bag of analyst opinions on the stock. While StockNews.com downgraded ICLR from “buy” to “hold,” Leerink Partnrs upgraded it to “strong-buy.” Several other firms initiated coverage on the stock, including Goldman Sachs and Truist Financial, with “buy” ratings and varying price targets.

Overall, ICON Public currently holds a “Buy” consensus rating with a target price of $351.60, according to MarketBeat.

Despite the reduced price target, analysts remain optimistic about ICLR’s future performance. The company exceeded earnings expectations in its latest quarterly report, reporting $3.75 earnings per share, beating the consensus estimate of $3.68. Revenue also came in above expectations, reaching $2.10 billion, compared to analysts’ expectations of $2.14 billion.

Institutional investors are also bullish on ICLR, with 95.61% of the stock owned by hedge funds and other institutions. Several funds recently initiated or increased their positions in the company, including Riverview Trust Co, Livelsberger Financial Advisory, and GAMMA Investing LLC.

ICON Public, a leading clinical research organization, specializes in supporting the development and commercialization of pharmaceutical and biotechnology products. The company provides a range of services from compound selection to Phase I-IV clinical studies.

Despite the recent price target reduction, the overall sentiment towards ICON Public remains positive. The company’s strong financial performance and the continued interest from institutional investors suggest that ICLR remains a compelling investment opportunity in the medical research sector.

Read More